To access this material please log in or register

Register Authorize

Cardio-oncology: Current aspects in diagnostics for cardiovascular complications of antitumor therapy

Vasyuk Yu. A.1, Shkolnik E. L.1, Nesvetov V. V.1, Shkolnik L. D.2, Selezneva M. G.2
1 – Federal State Budgetary Educational Institution of Higher Education, "A. I. Evdokimov Moscow State University for Medicine and Dentistry" of the Ministry of Health of the Russian Federation, Delegatskaya 20, Bld. 1, Moscow 127473
2 – State Budgetary Institution of Health Care, "Municipal Clinical Hospital #5 of the Health Care Department of Moscow City", Stromynka 7, Moscow 107014

Keywords: anthracycline cardiotoxicity, diagnostics, myocardial deformation, myocardial fibrosis markers, chemotherapy

DOI: 10.18087/rhfj.2016.6.2327

Cardiovascular and oncological diseases are the major causes for morbidity and mortality in industrial countries. Current strategies of therapy for oncological diseases have improved patients’ survival; however, these therapies are associated with serious cardiovascular complications. Current therapeutic schedules for oncological diseases include several chemotherapies, which generally induce pronounced cardiotoxicity. Myocardial dysfunction can develop during administration of chemotherapy, which destructs myocytes, such as anthracyclines or drugs indirectly impairing the LV contractility (alkylating agents, taxanes, monoclonal antibodies, and tyrosine kinase inhibitors). Besides, treatment of oncological diseases may be associated with development of cardiovascular diseases, such as AH, vasospastic or thromboembolic myocardial ischemia, as well as formation of myocardial fibrosis with subsequent cardiac rhythm and conduction disorders, which can be life-threatening. Early and late effects of radiation therapy to the chest may result in development of radiation-induced heart disease, including pericarditis, myocardial fibrosis, secondary cardiomyopathy, IHD, heart valve disease, and arrhythmias resulting from myocardial fibrosis. Therefore, developing a strategy for prevention or diminishment of damage to the cardiovascular system in the process of treatment of oncological diseases is a very relevant task.
  1. Yeh ET, Bickford CL. Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. J Am Coll Cardiol. 2009 Jun 16;53 (24):2231–47.
  2. Bonow RO, Bennett S, Casey DE, Ganiats TG, Hlatky MA, Konstam MA et al. ACC/AHA clinical performance measures for adults with chronic heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures (Writing Committee to Develop Heart Failure Clinical Performance Measures): endorsed by the Heart Failure Society of America. Circulation. 2005 Sep 20;112 (12):1853–87.
  3. Felker GM, Thompson RE, Hare JM, Hruban RH, Clemetson DE, Howard DL et al. Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N Engl J Med. 2000 Apr 13;342 (15):1077–84.
  4. Bovelli D, Plataniotis G, Roila F. Cardiotoxicity of chemotherapeutic agents and radiotherapy-related heart disease: ESMO Clinical Practice Guidelines. Ann Oncol. 2010 May;21 (Suppl 5):v277–82.
  5. Albini A, Pennesi G, Donatelli F, Cammarota R , De Flora S, Noonan DM. Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention. J Natl Cancer Inst. 2010 Jan 6;102 (1):14–25.
  6. Curigliano G, Cardinale D, Suter T, Plataniotis G, de Azambuja E, Sandri MT et al. Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines. Ann Oncol. 2012 Oct;23 (Suppl 7):vii155–66.
  7. Plana JC, Galderisi M, Barac A, Ewer MS, Ky B, Scherrer-Crosbie M et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging. 2014 Oct;15 (10):1063–93.
  8. Agha H, Shalaby L, Attia W, Abdelmohsen G, Aziz OA, Rahman MY. Early ventricular dysfunction after anthracycline chemotherapy in children. Pediatr Cardiol. 2016 Mar;37 (3):537–44.
  9. Berk BC, Fujiwara K, Lehoux S. ECM remodeling in hypertensive heart disease. J Clin Invest. 2007 Mar;117 (3):568–75.
  10. Mondillo S, Galderisi M, Mele D, Cameli M, Lomoriello VS, Zaca V et al. Speckle-tracking echocardiography: a new technique for assessing myocardial function. J Ultrasound Med. 2011 Jan;30 (1):71–83.
  11. Takigiku K, Takeuchi M, Izumi C, Yuda S, Sakata K, Ohte N et al. Normal range of left ventricular 2-dimensional strain: Japanese Ultrasound Speckle Tracking of the Left Ventricle ( JUSTICE) study. Circ J. 2012;76 (11):2623–32.
  12. Несветов В.В., Школьник Е.Л., Васюк Ю.А. Значение глобальной продольной систолической деформации по двухмерному изображению для ранней диагностики кардиотоксического действия химиопрепаратов (предварительные результаты). Журнал Сердечная Недостаточность. 2013;14 (3):127–30 [Nesvetov V.V., Shkol`nik E. L., Vasyuk Yu.A. Znachenie global`noj prodol`noj sistolicheskoj deformaczii po dvuxmernomu izobrazheniyu dlya rannej diagnostiki kardiotoksicheskogo dejstviya ximiopreparatov (predvaritel`ny`e rezul`taty`). Zhurnal Serdechnaya Nedostatochnost`. 2013;14 (3):127–30].
  13. Biswas M, Sudhakar S, Nanda NC, Buckberg G, Pradhan M, Roomi AU et al. Two- and three-dimensional speckle tracking echocardiography: clinical applications and future directions. Echocardiography. 2013 Jan;30 (1):88–105.
  14. Tan TC, Scherrer-Crosbie M. Cardiac complications of chemotherapy: role of imaging. Curr Treat Options Cardiovasc Med. 2014 Apr;16 (4):296.
  15. Tarr A, Stoebe S, Tuennemann J, Baka Z, Pfeiffer D, Varga A, Hagendorff A. Early detection of cardiotoxicity by 2D and 3D deformation imaging in patients receiving chemotherapy. Echo Res Pract. 2015 Sep 1;2 (3):81–8.
  16. Thavendiranathan P, Poulin F, Lim KD, Plana JC, Woo A, Marwick TH. Use of myocardial strain imaging by echocardiography for the early detection of cardiotoxicity in patients during and after cancer chemotherapy: a systematic review. J Am Coll Cardiol. 2014 Jul 1;63 (25 Pt A): 2751–68.
  17. Siegel R , Ward E, Brawley O, Jemal A. Cancer statistics. Canc J Clin. 2011 Jul-Aug;61 (4):212–36.
  18. Stoodley PW, Richards DA, Meikle SR , Clarke J, Hui R , Thomas L. The potential role of echocardiographic strain imaging for evaluating cardiotoxicity due to cancer therapy. Heart Lung Circ. 2011 Jan;20 (1):3–9.
  19. Sawaya H, Sebag IA, Plana JC, Januzzi JL, Ky B, Tan TC et al. Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes and trastuzumab. Circ Cardiovasc Imaging. 2012 Sep 1;5 (5):596–603.
  20. Sawaya H, Sebag IA, Plana JC, Januzzi JL, Ky B, Cohen V et al. Early detection and prediction of cardiotoxicity in chemotherapy-treated patients. Am J Cardiol. 2011 May 1;107 (9):1375–80.
  21. Cardinale D, Sandri MT, Colombo A, Colombo N, Boeri M, Lamantia G et al. Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy. Circulation. 2004 Jun 8;109 (22):2749–54.
  22. Liu FT, Hsu DK, Zuberi RI, Kuwabara I, Chi EY, Henderson WR Jr. Expression and function of galectin-3, a beta-galactoside-binding lectin, in human monocytes and macrophages. Am J Pathol. 1995 Oct;147 (4):1016–28.
  23. Henderson NC, Sethi T. The regulation of inflammation by galectin-3. Immunol Rev. 2009 Jul;230 (1):160–71.
  24. Carrasco-Sanchez FJ, Aramburu-Bodas O, Salamanca-Bautista P, Morales-Rull JL, Galisteo-Almeda L, Paez-Rubio MI et al. Predictive value of serum galectin-3 levels in patients with acute heart failure with preserved ejection fraction. Int J Cardiol. 2013 Nov 5;169 (3):177–82.
  25. Klebanoff SJ. Myeloperoxidase: friend and foe. J Leukoc Biol. 2005 May;77 (5):598–625.
  26. Baldus S, Heitzer T, Eiserich JP, Lau D, Mollnau H, Ortak M et al. Myeloperoxidase enhances nitric oxide catabolism during myocardial ischemia and reperfusion. Free Radic Biol Med. 2004 Sep 15;37 (6):902–11.
  27. Daugherty A, Dunn JL, Rateri DL, Heinecke JW. Myeloperoxidase, a catalyst for lipoprotein oxidation, is expressed in human atherosclerotic lesions. J Clin Invest. 1994 Jul;94 (1):437–44.
  28. Ky B, Putt M, Sawaya H, French B, Januzzi JL Jr, Sebag IA et al. Early increases in multiple biomarkers predict subsequent cardiotoxicity in patients with breast cancer treated with doxorubicin, taxanes, and trastuzumab. J Am Coll Cardiol. 2014 Mar 4;63 (8):809–16.
  29. Rehman SU, Mueller T, Januzzi JL Jr. Characteristics of the novel interleukin family biomarker ST2 in patients with acute heart failure. J Am Coll Cardiol. 2008 Oct 28;52 (18):1458–65.
  30. Shah RV, Januzzi JL Jr. ST2: a novel remodeling biomarker in acute and chronic heart failure. Curr Heart Fail Rep. 2010 Mar;7 (1):9–14.
  31. Kohli P, Bonaca MP, Kakkar R , Kudinova AY, Scirica BM, Sabatine MS et al. Role of ST2 in non-ST-elevation acute coronary syndrome in the MERLIN-TIMI 36 trial. Clin Chem. 2012 Jan;58 (1):257–66.
  32. Jacob S, Pathak A, Franck D, Latorzeff I, Jimenez G, Fondard O et al. Early detection and prediction of cardiotoxicity after radiation therapy for breast cancer: the BACCARAT prospective cohort study. Radiat Oncol. 2016 Apr 7;11:54.
  33. Heidenreich PA, Hancock SL, Lee BK, Mariscal CS, Schnittger I. Asymptomatic cardiac disease following mediastinal irradiation. J Am Coll Cardiol. 2003 Aug 20;42 (4):743–9.
  34. Darby SC, Ewertz M, McGale P, Bennet AM, Blom-Goldman U, Bronnum D et al. Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med. 2013 Mar 14;368 (11):987–98.
  35. Heidenreich PA, Hancock SL, Vagelos RH, Lee BK, Schnittger I. Diastolic dysfunction after mediastinal irradiation. Am Heart J. 2005 Nov;150 (5):977–82.
Vasyuk Yu.A., Shkolnik E.L., Nesvetov V.V., Shkolnik L.D., Selezneva M.G. Cardio-oncology: Current aspects in diagnostics for cardiovascular complications of antitumor therapy. Russian Heart Failure Journal. 2016;17 (6):383–387

To access this material please log in or register

Register Authorize
Ru En